Ads
related to: when was yescarta approved- How YESCARTA® Works
Learn About YESCARTA®
Find Out How It Works.
- Find A Treatment Center
Locate Nearest Authorized
YESCARTA Treatment Center
- CAR T Eligibility
You May Be Eligible
Learn More
- The Treatment Process
CAR T Therapy
Learn About the Multi-Step Process
- How CAR T Can Help
Made From Your Own T Cells
Learn More
- Patient Testimonials
Hear Patients Stories
Watch Now
- How YESCARTA® Works
Search results
Results From The WOW.Com Content Network
Axicabtagene ciloleucel, sold under the brand name Yescarta, is a medication used for the treatment for large B-cell lymphoma that has failed conventional treatment. [8] T cells are removed from a person with lymphoma and genetically engineered to produce a specific T-cell receptor .
The acquisition was completed in October 2017, [7] when Kite Pharma's Yescarta became the first CAR-T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. [8]
As of 2023, it is also approved for all six commercially available CAR-T products for lymphoma, multiple myeloma and pediatric B-Cell precursor acute lymphoblastic leukemia: Yescarta, Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Abecma (idecabtagene vicleucel), and Kymriah ...
In October 2017, Kite Pharma's therapy, Yescarta (axicabtagene ciloleucel) became the first CAR-T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. [18]
CAR T cell therapies have been approved in China, Australia, Singapore, the United Kingdom, and some European countries. [135] In February 2022 Brazil approved tisagenlecleucel (Kymriah) treatment. [ 136 ]
2017 – First autologous CAR T-cell therapy tisagenlecleucel approved for the treatment of pediatric B-ALL; second autologous CAR T-cell therapy axicabtagene ciloleucel (Yescarta) is approved. 2020 – The first mRNA vaccines ( BNT162b2 , mRNA-1273 ), are developed for SARS-CoV-2 infection; this new technology completed design, testing, and ...
Ads
related to: when was yescarta approved